161 related articles for article (PubMed ID: 22228630)
1. New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 Bispecific antibody for tumor targeting.
Groth A; Salnikov AV; Ottinger S; Gladkich J; Liu L; Kallifatidis G; Salnikova O; Ryschich E; Giese N; Giese T; Momburg F; Büchler MW; Moldenhauer G; Herr I
Clin Cancer Res; 2012 Feb; 18(4):1028-38. PubMed ID: 22228630
[TBL] [Abstract][Full Text] [Related]
2. Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma.
Salnikov AV; Groth A; Apel A; Kallifatidis G; Beckermann BM; Khamidjanov A; Ryschich E; Büchler MW; Herr I; Moldenhauer G
J Cell Mol Med; 2009 Sep; 13(9B):4023-33. PubMed ID: 20196789
[TBL] [Abstract][Full Text] [Related]
3. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
Schlereth B; Fichtner I; Lorenczewski G; Kleindienst P; Brischwein K; da Silva A; Kufer P; Lutterbuese R; Junghahn I; Kasimir-Bauer S; Wimberger P; Kimmig R; Baeuerle PA
Cancer Res; 2005 Apr; 65(7):2882-9. PubMed ID: 15805290
[TBL] [Abstract][Full Text] [Related]
4. An epithelial cell adhesion molecule- and CD3-bispecific antibody plus activated T-cells can eradicate chemoresistant cancer stem-like pancreatic carcinoma cells in vitro.
Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M; Morisaki T
Anticancer Res; 2014 Aug; 34(8):4509-19. PubMed ID: 25075094
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.
Amann M; Brischwein K; Lutterbuese P; Parr L; Petersen L; Lorenczewski G; Krinner E; Bruckmeier S; Lippold S; Kischel R; Lutterbuese R; Kufer P; Baeuerle PA; Schlereth B
Cancer Res; 2008 Jan; 68(1):143-51. PubMed ID: 18172306
[TBL] [Abstract][Full Text] [Related]
6. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells.
Chang CH; Wang Y; Li R; Rossi DL; Liu D; Rossi EA; Cardillo TM; Goldenberg DM
Cancer Res; 2017 Oct; 77(19):5384-5394. PubMed ID: 28819027
[TBL] [Abstract][Full Text] [Related]
8. Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110.
Deisting W; Raum T; Kufer P; Baeuerle PA; Münz M
PLoS One; 2015; 10(10):e0141669. PubMed ID: 26510188
[TBL] [Abstract][Full Text] [Related]
9. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
[TBL] [Abstract][Full Text] [Related]
10. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells.
Cioffi M; Dorado J; Baeuerle PA; Heeschen C
Clin Cancer Res; 2012 Jan; 18(2):465-74. PubMed ID: 22096026
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.
Amann M; D'Argouges S; Lorenczewski G; Brischwein K; Kischel R; Lutterbuese R; Mangold S; Rau D; Volkland J; Pflanz S; Raum T; Münz M; Kufer P; Schlereth B; Baeuerle PA; Friedrich M
J Immunother; 2009 Jun; 32(5):452-64. PubMed ID: 19609237
[TBL] [Abstract][Full Text] [Related]
12. Cell surface delivery of TRAIL strongly augments the tumoricidal activity of T cells.
de Bruyn M; Wei Y; Wiersma VR; Samplonius DF; Klip HG; van der Zee AG; Yang B; Helfrich W; Bremer E
Clin Cancer Res; 2011 Sep; 17(17):5626-37. PubMed ID: 21753155
[TBL] [Abstract][Full Text] [Related]
13. Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody.
Morecki S; Lindhofer H; Yacovlev E; Gelfand Y; Ruf P; Slavin S
Exp Hematol; 2008 Aug; 36(8):997-1003. PubMed ID: 18495330
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
[TBL] [Abstract][Full Text] [Related]
15. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
[TBL] [Abstract][Full Text] [Related]
16. Intrahepatically transplanted human cord blood cells reduce SW480 tumor growth in the presence of bispecific EpCAM/CD3 antibody.
Wulf-Goldenberg A; Eckert K; Fichtner I
Cytotherapy; 2011 Jan; 13(1):108-13. PubMed ID: 20839999
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic carcinoma-specific immunotherapy using novel tumor specific cytotoxic T cells.
Lei J; Wu Z; Jiang Z; Li J; Zong L; Chen X; Duan W; Xu Q; Zhang L; Han L; Ma Q; Wang Z; Zhang D
Oncotarget; 2016 Dec; 7(50):83601-83610. PubMed ID: 27876704
[TBL] [Abstract][Full Text] [Related]
18. Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes.
Schmitt M; Schmitt A; Reinhardt P; Thess B; Manfras B; Lindhofer H; Riechelmann H; Wiesneth M; Gronau S
Int J Oncol; 2004 Oct; 25(4):841-8. PubMed ID: 15375531
[TBL] [Abstract][Full Text] [Related]
19. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3.
Schlereth B; Kleindienst P; Fichtner I; Lorenczewski G; Brischwein K; Lippold S; da Silva A; Locher M; Kischel R; Lutterbüse R; Kufer P; Baeuerle PA
Cancer Immunol Immunother; 2006 Jul; 55(7):785-96. PubMed ID: 16187083
[TBL] [Abstract][Full Text] [Related]
20. EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy.
Mitra M; Kandalam M; Harilal A; Verma RS; Krishnan UM; Swaminathan S; Krishnakumar S
Mol Vis; 2012; 18():290-308. PubMed ID: 22328825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
